Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Doubling Down on Mutant RAS Can MEK or Break Leukemia.

Cell - 23 Feb 2017

Tothova Zuzana, Ebert Benjamin L

Abstract excerpt

Targeting of the RAS pathway has long been a critical therapeutic challenge in oncology. Burgess et al. examine how the relative expression of mutant and wild-type KRAS modulates clonal fitness and sensitivity to MEK inhibitors in a model of KrasG12D mutant acute myeloid leukemia and propose its use as a predictive biomarker.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, ras
Share to KRAS gene
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to ras Proteins

Source

Identifiers

PMID: 28235190
DOI: 10.1016/j.cell.2017.02.013

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Doubling Down on Mutant RAS Can MEK or Break Leukemia.PMID 28235190Read ↗

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.Semantic proximity Read ↗

Somatic activation of oncogenic <i>Kras</i> in hematopoietic cells initiates a rapidly fatal myeloproliferative disorderSemantic proximity Read ↗

Oncogenic Kras Initiates Leukemia in Hematopoietic Stem CellsSemantic proximity Read ↗

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasmsSemantic proximity Read ↗

MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene AddictionSemantic proximity Read ↗

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.Semantic proximity Read ↗

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivoSemantic proximity Read ↗

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.Semantic proximity Read ↗

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.